The treatment of diabetic macular edema with intravitreal bevacizumab in users of the Brazilian public health system
2024

Bevacizumab Treatment for Diabetic Macular Edema in Brazil

Sample size: 130 publication Evidence: moderate

Author Information

Author(s): Ibrahim Larissa Fouad, Soares Aleida Nazareth, Costa Lucas Assis, Domingues Thabata Machado Correia, de Souza Alessandra Hubner

Primary Institution: Faculdade Ciências Médicas de Minas Gerais

Hypothesis

This study aimed to evaluate DME treatment with antiangiogenic drugs, in terms of both visual and economic outcomes within the Brazilian public health system.

Conclusion

The study showed positive clinical results from bevacizumab treatment of DME, with 63.8% of participants improving their visual acuity after one year.

Supporting Evidence

  • 62% of patients received three injections over 12 months.
  • 63.84% of participants showed improvements in their best corrected visual acuity after 12 months.
  • Median reduction in central macular thickness was 39.5 µm after 12 months.
  • The total treatment cost for 130 eyes was R$92,577.02.

Takeaway

Doctors used a medicine called bevacizumab to help people with eye problems from diabetes, and many of them saw their vision get better after a year.

Methodology

This was a single-center retrospective study collecting data from medical records of adults diagnosed with DME treated with intravitreal bevacizumab.

Limitations

The study had a limited follow-up period and fewer injections compared to other studies may have affected visual outcomes.

Participant Demographics

The mean age of participants was 63.3 years, with 53% men and 47% women.

Digital Object Identifier (DOI)

10.5935/0004-2749.2024-0146

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication